CervoMed to Participate in the BIO CEO and Investor Conference
CervoMed Inc. (CRVO)
Company Research
Source: GlobeNewswire
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will present at the BIO CEO and Investor Conference on February 26, 2024, being held in New York, NY and participate in one-on-one investor meetings. Presentation Details Format: Corporate presentation Date: Monday, February 26, 2024Time: 2:00 PM ET To learn more about the BIO CEO and Investor Conference please visit https://bcic.bio.org/. About CervoMedCervoMed Inc. is a clinical-stage company focused on developing treatments for degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease
Show less
Read more
Impact Snapshot
Event Time:
CRVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVO alerts
High impacting CervoMed Inc. news events
Weekly update
A roundup of the hottest topics
CRVO
News
- CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesGlobeNewswire
- CervoMed to Participate in Upcoming Investor ConferencesGlobeNewswire
- CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare InvestorsGlobeNewswire
- CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024GlobeNewswire
CRVO
Sec Filings
- 5/10/24 - Form S-1
- 4/29/24 - Form DEF
- 4/23/24 - Form 8-K
- CRVO's page on the SEC website